Search for Stocks /

Global Health Ltd Q3 FY26 — ₹1,121 Cr Quarterly Revenue, 3,435 Beds, ₹4,122 Cr Capex, and a Valuation That’s Flexing Harder Than ICU Utilisation

Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.

1. At a Glance

Global Health Ltd, better known to the stock market as Medanta, is having one of those “everything is happening at once” phases. ₹29,408 Cr market cap, stock price hovering around ₹1,094, down ~21% in six months, while operationally the company is sprinting like a resident doctor on a 36-hour shift. Q3 FY26 revenue clocked in at ₹1,121 Cr (YoY +18.8%), PAT ₹95 Cr (YoY -13.2%), average occupancy at 63.4%, ARPOB at a chunky ₹66,055, and 3,435 installed beds already sweating for returns.

On paper, ROCE is 19.7%, ROE 16.5%, debt to equity a civilised 0.25. On the ground, Medanta is opening hospitals like a real estate developer on Red Bull—Noida, Ranchi, Patna expansion, Mumbai mega project, South Delhi, Pitampura, Guwahati. The market, meanwhile, is asking just one question: Boss, capex toh sexy hai, but paisa kab banega?

Stick around. This is not a boring hospital story. This is a high-stakes ICU drama with valuation multiples watching from the gallery.


2. Introduction

Hospitals are supposed to be boring businesses. Beds, doctors, patients, cash flows that look like annuity streams, and valuations that quietly compound. Medanta didn’t get that memo.

Global Health Ltd is behaving like a startup with a balance sheet. In the last few years, it has transitioned from a single-flagship Gurugram hospital into a pan-North and East India tertiary care platform. And now, it’s flirting aggressively with West India too.

But here’s the fun part. The stock market already knows Medanta is good. That’s why it trades at ~52x trailing earnings and ~29x EV/EBITDA. So the game is no longer “Is this a good hospital chain?” The game is:

Can Medanta execute a ₹4,122 Cr capex plan without blowing ROCE, margins, or investor patience?

Q3 FY26 gave us a trailer. Revenue growth strong. Occupancy improving. But PAT dipped thanks to Noida bleeding EBITDA, labour cost exceptional charges, and depreciation kicking harder as new hospitals come online.

So are we watching a temporary digestion phase… or the start of margin indigestion? Let’s scrub in.


3. Business Model – WTF Do They Even Do?

Medanta runs tertiary and

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →